Capricor Therapeutics Inc Stock price Nasdaq
Equities
US14070B1017
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 21.4M | Sales 2025 * | 89.52M | Capitalization | 213M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 8M | EV / Sales 2024 * | 9.93 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.37 x |
P/E ratio 2024 * |
-7.02
x | P/E ratio 2025 * |
69.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.81% |
Latest transcript on Capricor Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
1st Jan change | Capi. | |
---|---|---|
+2.56% | 108B | |
+10.02% | 104B | |
+6.49% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |